Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

  • Posts
    • AACR18
    • AACR17
    • AACR16
    • AACR15
    • AACR14
    • AACR IO
    • AAI ASGCT 2015 New Orleans
    • ASCO-SITC
    • ASCO18
    • ASCO17
    • ASCO16
    • ASCO15
    • ASCO14
    • ASCO GU18
    • ASCO GI18
    • ASCO GI 2017
    • ASCO GU CI 2016
    • ASCO GI GU 2015
    • ASCO GI GU 2014
    • ASH17
    • ASH16
    • ASH15
    • ASH14
    • ASH13
    • AUA 2015
    • AUA 2014
    • BMT Tandem
    • CIML40
    • EACR
    • EAU 2015 Congress
    • EBMT15
    • ESMO IO
    • ESMO17
    • ESMO16
    • ECC 2015
    • ESMO14
    • ECC 2013
    • European Breast Cancer Conference
    • European Lung Cancer Conf
    • JPM18
    • JPM17
    • JPM16
    • JPM15
    • JPM14
    • Miami Breast Cancer Conference
    • Targets17
    • Mol Targets 2016
    • Molecular Targets
    • SABCS17
    • SABCS16
    • SABCS15
    • SABCS14
    • SABCS13
    • SGO
    • SITC 2017
    • SITC 2016
    • SITC 2015
    • SITC 2014
    • WCLC
  • About
  • Contact
  • Interviews
  • Immuno-Oncology
  • Premium Content
  • Pricing
  • Login

  • What was old in cancer research is new again

    Read more

  • New Insights on BCMA BiTEs and CAR T cell therapies in Myeloma

    Read more

  • Preview of WCLC 2018 – what’s new in lung cancer?

    Read more

  • New targets and indications in oncology R&D

    Read more

  • Pathways to success with NK cell therapy

    Read more

  • Learnings from IO combinations and where we’re headed

    Read more

  • Armored CAR-T cell therapies and commercial threats from the East

    Read more

  • Targeting immunosuppression and other stories – are we ready for prime time yet?

    Read more

  • Picking PARP inhibitors apart

    Read more

  • When oncogenic and immunogenic worlds collide…

    Read more

  • Could a Novel Cell Therapy replace CAR T Cell Therapy?

    Read more
E

What was old in cancer research is new again

A fresh look at a class of targeted therapy agents that are beginning to look promising in some cancer patients

View post
E

New Insights on BCMA BiTEs and CAR T cell therapies in Myeloma

Update on BCMA, SLAMF7 and other targets in multiple myeloma

View post
E

Preview of WCLC 2018 – what’s new in lung cancer?

What to watch out for at WCLC2018 in Toronto later this month

View post

Terms of Use & Privacy Policy
Copyright © 2010-18 Biotech Strategy Blog

Sign Up for New Post Alerts
error: Content is protected !!